Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9615977 | 0.89 | SIGMAR1 (0.54) | SIGMAR1OPRD1AVPR1A | |
| SCHEMBL6346542 | 0.84 | SIGMAR1 (0.55) | SIGMAR1OPRD1 | |
| SCHEMBL29790950 | 0.81 | SIGMAR1 (0.49) | SIGMAR1OPRD1AVPR1A | |
| SCHEMBL11328335 | 0.79 | SIGMAR1 (0.50) | SIGMAR1OPRD1 | |
| SCHEMBL30389740 | 0.79 | SIGMAR1 (0.50) | SIGMAR1OPRD1 | |
| SCHEMBL3400315 | 0.78 | SIGMAR1 (0.49) | SIGMAR1OPRD1AVPR1A | |
| SCHEMBL24203802 | 0.77 | ATM (0.40) | AVPR1A | |
| SCHEMBL30574142 | 0.77 | AVPR1A (0.39) | AVPR1A | |
| SCHEMBL15963043 | 0.76 | SIGMAR1 (0.48) | SIGMAR1OPRD1AVPR1A | |
| SCHEMBL8871048 | 0.76 | SIGMAR1 (0.53) | SIGMAR1OPRD1AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20050261327-A1 | 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation | MERCK & CO., INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261327-A1 | 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation | BDKRB1, BDKRB2, LTB4R2 | SIGMAR1 1107/4885OPRD1 163/4885AVPR1A 157/4885 |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | KEAP1, NFE2L2, NQO1 | SIGMAR1 1825/4885OPRD1 1170/4885AVPR1A 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.